EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial

Mark Goldin, Nikolaos Tsaftaridis, Ioannis Koulas, Jeffrey Solomon, Michael Qiu, Tungming Leung, Kolton Smith, Kanta Ochani, Thomas McGinn, Alex C Spyropoulos

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.07.025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Mark Goldin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, New Hyde Park, New York, USA; Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA; Dep…. Hauptthemen laut MEDLINE: COVID-19, Venous Thromboembolism, Decision Support Systems, Clinical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: AHRQ, Janssen Scientific Affairs LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inpatient and extended postdischarge thromboprophylaxis of COVID-19 patients remains suboptimal despite antithrombotic guidelines. OBJECTIVES: To determine whether a novel electronic health record-agnostic clinical decision support (CDS) tool incorporating the International Medical Prevention Registry on Venous Thromboembolism plus D-dimer (IMPROVE-DD) venous thromboembolism (VTE) scores increases appropriate inpatient and extended postdischarge thromboprophylaxis and improves outcomes in COVID-19 inpatients. METHODS: This post hoc analysis of the IMPROVE-DD cluster randomized trial evaluated thromboprophylaxis CDS among COVID-19 inpatients at 4 New York hospitals between December 21, 2020, and January 21, 2022. Hospitals were randomized 1:1 to CDS (intervention, n = 2) vs no CDS (usual care, n = 2). The primary outcome was rate of appropriate thromboprophylaxis. Secondary outcomes included rates of major thromboembolism, all-cause and VTE-related readmissions and death, major bleeding (MB), and all-cause mortality 30 days after discharge. RESULTS: Two thousand four hundred fifty-two COVID-19 inpatients were analyzed (CDS, 1355; no CDS, 1097). Mean age was 73.7 ± 9.37 years; 50.1% of participants were male. CDS adoption was 96.8% (intervention group). CDS was associated with increased appropriate at-discharge extended thromboprophylaxis (42.6% vs 28.8%; odds ratio [OR], 1.83; 95% CI, 1.39-2.41; P < .001). CDS was associated with reduced VTE (OR, 0.54; 95% CI, 0.39-0.75; P < .001), arterial thromboembolism (OR, 0.10; 95% CI, 0.01-0.81; P = .01), total thromboembolism (OR, 0.50; 95% CI, 0.36-0.69; P < .001), and 30-day all-cause readmission/death (OR, 0.78; 95% CI, 0.62-0.99; P = .04). There were no differences in MB, VTE-related readmissions/death, or all-cause mortality. CONCLUSION: Electronic health record-agnostic CDS incorporating IMPROVE-DD VTE scores had high adoption, was associated with increased appropriate at-discharge extended thromboprophylaxis, and reduced thromboembolism and all-cause readmission/death without increasing MB in COVID-19 inpatients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Venous ThromboembolismDecision Support Systems, ClinicalHumansMaleFemaleAgedMiddle AgedElectronic Health RecordsFibrin Fibrinogen Degradation ProductsAnticoagulantsSARS-CoV-2HospitalizationPatient DischargeHemorrhageTreatment OutcomeAged, 80 and overInpatientsNew YorkRisk FactorsPatient Readmission

Stichwörter der Autor:innen

COVID-19clinical decision supporthealth informaticsprophylaxisthrombosis

Substanzen

Fibrin Fibrinogen Degradation Productsfibrin fragment DAnticoagulants

Autor:innen und Institutionen

  • Northwell, New Hyde Park, New York, USA; Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA; Department of Medicine, Donald and Barbara Zucker School of Medicine at H…
  • Northwell, New Hyde Park, New York, USA; Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Northwell, New Hyde Park, New York, USA; Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York, USA; Department of Medicine, Jacobi Medical Center, Albert Einstein College of…
  • Northwell, New Hyde Park, New York, USA; Biostatistics Unit, Office of Academic Affairs, Northwell, Hempstead, New York, USA.
  • Northwell, New Hyde Park, New York, USA; Department of Internal Medicine, Lenox Hill Hospital at Northwell Health, New York, New York, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; CommonSpirit Health, Chicago, Illinois, USA.

Förderung

  • AHRQ
  • Janssen Scientific Affairs LLC

Zitieren

APA

Goldin, M., Tsaftaridis, N., Koulas, I., Solomon, J., Qiu, M., Leung, T., Smith, K., Ochani, K., McGinn, T., & Spyropoulos, A. C. (2024). Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.07.025

Vancouver

Goldin M, Tsaftaridis N, Koulas I, Solomon J, Qiu M, Leung T, et al. Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.07.025

BibTeX
@article{Goldin2024,
  author = {Goldin, Mark and Tsaftaridis, Nikolaos and Koulas, Ioannis and Solomon, Jeffrey and Qiu, Michael and Leung, Tungming and Smith, Kolton and Ochani, Kanta and McGinn, Thomas and Spyropoulos, Alex C},
  title = {Universal clinical decision support tool for thromboprophylaxis in hospitalized COVID-19 patients: post hoc analysis of the IMPROVE-DD cluster randomized trial},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.07.025}
}
Kostenlos starten →